Loring Wolcott & Coolidge Fiduciary Advisors LLP MA Trims Stake in IQVIA Holdings Inc. (NYSE:IQV)

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA decreased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 64.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,465 shares of the medical research company's stock after selling 9,745 shares during the quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's holdings in IQVIA were worth $1,131,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the 3rd quarter worth about $27,000. Synergy Asset Management LLC purchased a new position in IQVIA in the fourth quarter worth about $33,000. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. Assetmark Inc. grew its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after buying an additional 196 shares during the last quarter. Finally, UMB Bank n.a. raised its holdings in IQVIA by 74.4% in the 3rd quarter. UMB Bank n.a. now owns 232 shares of the medical research company's stock worth $55,000 after acquiring an additional 99 shares during the last quarter. 89.62% of the stock is owned by institutional investors.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of the business's stock in a transaction that occurred on Tuesday, December 3rd. The stock was purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have commented on IQV. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 target price on shares of IQVIA in a report on Monday. Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Leerink Partners reiterated an "outperform" rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Finally, Morgan Stanley increased their price objective on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $251.67.

IQVIA Price Performance

NYSE:IQV traded down $3.25 on Wednesday, reaching $197.64. 1,044,006 shares of the company's stock traded hands, compared to its average volume of 1,411,836. The firm has a market cap of $35.87 billion, a PE ratio of 26.35, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a quick ratio of 0.81, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock has a 50-day simple moving average of $200.77 and a 200-day simple moving average of $218.81. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.